Analysts’ Top Healthcare Picks: Rexahn Pharma (RNN), Nabriva (NBRV)


There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Rexahn Pharma (RNN) and Nabriva (NBRV) with bullish sentiments.

Rexahn Pharma (RNN)

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Rexahn Pharma today and set a price target of $23. The company’s shares opened today at $5.29, close to its 52-week low of $4.75.

According to TipRanks.com, Pantginis is a 2-star analyst with an average return of 0.0% and a 36.5% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Iovance Biotherapeutics Inc, and Checkpoint Therapeutics Inc.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Rexahn Pharma with a $23 average price target.

See today’s analyst top recommended stocks >>

Nabriva (NBRV)

H.C. Wainwright analyst Ed Arce maintained a Buy rating on Nabriva today and set a price target of $7. The company’s shares opened today at $2.63.

According to TipRanks.com, Arce is a 4-star analyst with an average return of 10.5% and a 39.2% success rate. Arce covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Arcturus Therapeutics Ltd, and Melinta Therapeutics Inc.

Currently, the analyst consensus on Nabriva is a Strong Buy with an average price target of $7.70, a 192.8% upside from current levels. In a report issued on May 1, Northland Securities also assigned a Buy rating to the stock with a $12.50 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts